Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Cash Flow (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Net Cash Flow data on record, last reported at $16.1 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 1660.35% year-over-year to $16.1 million; the TTM value through Dec 2025 reached $72.0 million, up 215.96%, while the annual FY2025 figure was $72.0 million, 215.96% up from the prior year.
  • Net Cash Flow reached $16.1 million in Q4 2025 per MIRM's latest filing, down from $53.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $147.9 million in Q2 2023 and bottomed at -$69.2 million in Q2 2024.
  • Average Net Cash Flow over 5 years is $7.7 million, with a median of $3.7 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: plummeted 265.78% in 2024, then skyrocketed 1660.35% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $75.5 million in 2021, then tumbled by 110.39% to -$7.8 million in 2022, then plummeted by 114.78% to -$16.8 million in 2023, then skyrocketed by 105.42% to $913000.0 in 2024, then surged by 1660.35% to $16.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $16.1 million in Q4 2025, $53.6 million in Q3 2025, and $14.1 million in Q2 2025.